{"id":6751,"date":"2024-08-29T07:30:33","date_gmt":"2024-08-29T11:30:33","guid":{"rendered":"https:\/\/bridgebio.local\/news\/auto-draft\/"},"modified":"2024-08-28T20:26:08","modified_gmt":"2024-08-29T00:26:08","slug":"bridgebio-to-present-additional-analyses-from-the-phase-3-attribute-cm-trial-of-acoramidis-in-patients-with-transthyretin-amyloid-cardiomyopathy-attr-cm-at-the-esc-congress-2024-and-the-hfsa-annual","status":"publish","type":"post","link":"https:\/\/bridgebio.com\/news\/bridgebio-to-present-additional-analyses-from-the-phase-3-attribute-cm-trial-of-acoramidis-in-patients-with-transthyretin-amyloid-cardiomyopathy-attr-cm-at-the-esc-congress-2024-and-the-hfsa-annual\/","title":{"rendered":"BridgeBio to Present Additional Analyses from the Phase 3 ATTRibute-CM Trial of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the ESC Congress 2024 and the HFSA Annual Meeting 2024"},"content":{"rendered":"<p align=\"left\"><strong>PALO ALTO, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE)<\/strong> &#8212; BridgeBio Pharma, Inc. (Nasdaq: BBIO) (\u201cBridgeBio\u201d or the \u201cCompany\u201d), a commercial-stage biopharmaceutical company focused on genetic diseases, announced today that additional data on clinical outcomes from ATTRibute-CM, its Phase 3 study of acoramidis in ATTR-CM, will be presented at the European Society of Cardiology (ESC) Congress 2024, taking place in London, United Kingdom on August 30 \u2013 September 2, 2024 and the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2024, taking place in Atlanta, Georgia on September 27 &#8211; 30, 2024.<\/p>\n<p><strong><u>ESC Moderated Poster details:<\/u><\/strong><\/p>\n<p><strong>Increase in Serum TTR Levels Observed with Acoramidis Treatment in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM): Insights From ATTRibute-CM and Its Open-Label Extension<\/strong><br \/>\n<strong>Session Title:\u00a0<\/strong>Cardiac amyloidosis: diagnosis and outcomes<br \/>\n<strong>Presenter:\u00a0<\/strong>Dr. Mathew S. Maurer, Columbia University Irving Medical Center, New York, United States of America<br \/>\n<strong>Date\/time:\u00a0<\/strong>Friday, August 30 at 10:00 am ET<br \/>\n<strong>Location:<\/strong>\u00a0Station 10 &#8211; Research Gateway<\/p>\n<p><strong><u>HFSA Oral Presentation details:<\/u><\/strong><\/p>\n<p><strong>Acoramidis Improves Clinical Outcomes in Patients with Transthyretin Amyloid Cardiomyopathy: A Post Hoc Recurrent Event Analysis of ATTRibute-CM<\/strong><br \/>\n<strong>Session Title:\u00a0<\/strong>Oral Abstract Sessions<br \/>\n<strong>Presenter<\/strong>: Dr. Daniel P. Judge, Medical University of South Carolina, United States of America and Co-Chair of the ATTRibute-CM Steering Committee<br \/>\n<strong>Date\/time<\/strong>: Saturday, September 28 at 4:36 pm ET<br \/>\n<strong>Location<\/strong>: Oral Abstract Stage | Exhibit Hall<\/p>\n<p>The presentations will be available following the sessions on the Presentations page within the Investors section of the BridgeBio website at\u00a0<a href=\"https:\/\/investor.bridgebiodev.wpengine.com\/\" target=\"_blank\" rel=\"nofollow noopener\">https:\/\/investor.bridgebiodev.wpengine.com<\/a>.<\/p>\n<p><strong>About BridgeBio Pharma, Inc.<\/strong><br \/>\nBridgeBio Pharma (BridgeBio) is a commercial-stage biopharmaceutical company founded to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio\u2019s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015, and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit\u00a0<a href=\"http:\/\/bridgebio.com\/\" target=\"_blank\" rel=\"nofollow noopener\">bridgebiodev.wpengine.com<\/a>\u00a0and follow us on\u00a0<a href=\"https:\/\/www.linkedin.com\/company\/6824982\/admin\/\" target=\"_blank\" rel=\"nofollow noopener\">LinkedIn<\/a>,\u00a0<a href=\"https:\/\/twitter.com\/BridgeBioPharma\" target=\"_blank\" rel=\"nofollow noopener\">Twitter<\/a>\u00a0and\u00a0<a href=\"https:\/\/www.facebook.com\/profile.php?id=61561087329761\" target=\"_blank\" rel=\"nofollow noopener\">Facebook<\/a>.<\/p>\n<p><strong>BridgeBio Contact:<\/strong><br \/>\nVikram Bali<br \/>\n<a href=\"mailto:contact@bridgebiodev.wpengine.com\" target=\"_blank\" rel=\"nofollow noopener\">contact@bridgebiodev.wpengine.com<\/a><br \/>\n(650)-789-8220<\/p>\n","protected":false},"excerpt":{"rendered":"<p>PALO ALTO, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) &#8212; BridgeBio Pharma, Inc. (Nasdaq: BBIO) (\u201cBridgeBio\u201d or the \u201cCompany\u201d), a commercial-stage biopharmaceutical company focused on genetic diseases, announced today that additional data on clinical outcomes from ATTRibute-CM, its Phase 3 study of acoramidis in ATTR-CM, will be presented at the European Society of Cardiology (ESC) Congress [&hellip;]<\/p>\n","protected":false},"author":38,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[8,10],"tags":[],"class_list":["post-6751","post","type-post","status-publish","format-standard","hentry","category-news","category-press-release"],"acf":{"people":false,"external_link":"","presentation":""},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>BridgeBio to Present Additional Analyses from the Phase 3 ATTRibute-CM Trial of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the ESC Congress 2024 and the HFSA Annual Meeting 2024 - BridgeBio<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/bridgebio.com\/news\/bridgebio-to-present-additional-analyses-from-the-phase-3-attribute-cm-trial-of-acoramidis-in-patients-with-transthyretin-amyloid-cardiomyopathy-attr-cm-at-the-esc-congress-2024-and-the-hfsa-annual\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BridgeBio to Present Additional Analyses from the Phase 3 ATTRibute-CM Trial of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the ESC Congress 2024 and the HFSA Annual Meeting 2024 - BridgeBio\" \/>\n<meta property=\"og:description\" content=\"PALO ALTO, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) &#8212; BridgeBio Pharma, Inc. (Nasdaq: BBIO) (\u201cBridgeBio\u201d or the \u201cCompany\u201d), a commercial-stage biopharmaceutical company focused on genetic diseases, announced today that additional data on clinical outcomes from ATTRibute-CM, its Phase 3 study of acoramidis in ATTR-CM, will be presented at the European Society of Cardiology (ESC) Congress [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/bridgebio.com\/news\/bridgebio-to-present-additional-analyses-from-the-phase-3-attribute-cm-trial-of-acoramidis-in-patients-with-transthyretin-amyloid-cardiomyopathy-attr-cm-at-the-esc-congress-2024-and-the-hfsa-annual\/\" \/>\n<meta property=\"og:site_name\" content=\"BridgeBio\" \/>\n<meta property=\"article:published_time\" content=\"2024-08-29T11:30:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-08-29T00:26:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/bridgebio.com\/wp-content\/uploads\/2019\/02\/BridgeBio_Share.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Holly Condon\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@BridgeBioPharma\" \/>\n<meta name=\"twitter:site\" content=\"@BridgeBioPharma\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Holly Condon\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/bridgebio.com\/news\/bridgebio-to-present-additional-analyses-from-the-phase-3-attribute-cm-trial-of-acoramidis-in-patients-with-transthyretin-amyloid-cardiomyopathy-attr-cm-at-the-esc-congress-2024-and-the-hfsa-annual\/\",\"url\":\"https:\/\/bridgebio.com\/news\/bridgebio-to-present-additional-analyses-from-the-phase-3-attribute-cm-trial-of-acoramidis-in-patients-with-transthyretin-amyloid-cardiomyopathy-attr-cm-at-the-esc-congress-2024-and-the-hfsa-annual\/\",\"name\":\"BridgeBio to Present Additional Analyses from the Phase 3 ATTRibute-CM Trial of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the ESC Congress 2024 and the HFSA Annual Meeting 2024 - BridgeBio\",\"isPartOf\":{\"@id\":\"https:\/\/bridgebio.com\/#website\"},\"datePublished\":\"2024-08-29T11:30:33+00:00\",\"dateModified\":\"2024-08-29T00:26:08+00:00\",\"author\":{\"@id\":\"https:\/\/bridgebio.com\/#\/schema\/person\/4add0b7d61d0ea7518a9f18377b57f96\"},\"breadcrumb\":{\"@id\":\"https:\/\/bridgebio.com\/news\/bridgebio-to-present-additional-analyses-from-the-phase-3-attribute-cm-trial-of-acoramidis-in-patients-with-transthyretin-amyloid-cardiomyopathy-attr-cm-at-the-esc-congress-2024-and-the-hfsa-annual\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/bridgebio.com\/news\/bridgebio-to-present-additional-analyses-from-the-phase-3-attribute-cm-trial-of-acoramidis-in-patients-with-transthyretin-amyloid-cardiomyopathy-attr-cm-at-the-esc-congress-2024-and-the-hfsa-annual\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/bridgebio.com\/news\/bridgebio-to-present-additional-analyses-from-the-phase-3-attribute-cm-trial-of-acoramidis-in-patients-with-transthyretin-amyloid-cardiomyopathy-attr-cm-at-the-esc-congress-2024-and-the-hfsa-annual\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/bridgebio.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BridgeBio to Present Additional Analyses from the Phase 3 ATTRibute-CM Trial of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the ESC Congress 2024 and the HFSA Annual Meeting 2024\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/bridgebio.com\/#website\",\"url\":\"https:\/\/bridgebio.com\/\",\"name\":\"BridgeBio\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/bridgebio.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/bridgebio.com\/#\/schema\/person\/4add0b7d61d0ea7518a9f18377b57f96\",\"name\":\"Holly Condon\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/bridgebio.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/32160078eac50cc259c3cf6057162339?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/32160078eac50cc259c3cf6057162339?s=96&d=mm&r=g\",\"caption\":\"Holly Condon\"},\"url\":\"https:\/\/bridgebio.com\/author\/holly-condonbridgebio-com\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BridgeBio to Present Additional Analyses from the Phase 3 ATTRibute-CM Trial of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the ESC Congress 2024 and the HFSA Annual Meeting 2024 - BridgeBio","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/bridgebio.com\/news\/bridgebio-to-present-additional-analyses-from-the-phase-3-attribute-cm-trial-of-acoramidis-in-patients-with-transthyretin-amyloid-cardiomyopathy-attr-cm-at-the-esc-congress-2024-and-the-hfsa-annual\/","og_locale":"en_US","og_type":"article","og_title":"BridgeBio to Present Additional Analyses from the Phase 3 ATTRibute-CM Trial of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the ESC Congress 2024 and the HFSA Annual Meeting 2024 - BridgeBio","og_description":"PALO ALTO, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) &#8212; BridgeBio Pharma, Inc. (Nasdaq: BBIO) (\u201cBridgeBio\u201d or the \u201cCompany\u201d), a commercial-stage biopharmaceutical company focused on genetic diseases, announced today that additional data on clinical outcomes from ATTRibute-CM, its Phase 3 study of acoramidis in ATTR-CM, will be presented at the European Society of Cardiology (ESC) Congress [&hellip;]","og_url":"https:\/\/bridgebio.com\/news\/bridgebio-to-present-additional-analyses-from-the-phase-3-attribute-cm-trial-of-acoramidis-in-patients-with-transthyretin-amyloid-cardiomyopathy-attr-cm-at-the-esc-congress-2024-and-the-hfsa-annual\/","og_site_name":"BridgeBio","article_published_time":"2024-08-29T11:30:33+00:00","article_modified_time":"2024-08-29T00:26:08+00:00","og_image":[{"width":1200,"height":600,"url":"https:\/\/bridgebio.com\/wp-content\/uploads\/2019\/02\/BridgeBio_Share.png","type":"image\/png"}],"author":"Holly Condon","twitter_card":"summary_large_image","twitter_creator":"@BridgeBioPharma","twitter_site":"@BridgeBioPharma","twitter_misc":{"Written by":"Holly Condon","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/bridgebio.com\/news\/bridgebio-to-present-additional-analyses-from-the-phase-3-attribute-cm-trial-of-acoramidis-in-patients-with-transthyretin-amyloid-cardiomyopathy-attr-cm-at-the-esc-congress-2024-and-the-hfsa-annual\/","url":"https:\/\/bridgebio.com\/news\/bridgebio-to-present-additional-analyses-from-the-phase-3-attribute-cm-trial-of-acoramidis-in-patients-with-transthyretin-amyloid-cardiomyopathy-attr-cm-at-the-esc-congress-2024-and-the-hfsa-annual\/","name":"BridgeBio to Present Additional Analyses from the Phase 3 ATTRibute-CM Trial of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the ESC Congress 2024 and the HFSA Annual Meeting 2024 - BridgeBio","isPartOf":{"@id":"https:\/\/bridgebio.com\/#website"},"datePublished":"2024-08-29T11:30:33+00:00","dateModified":"2024-08-29T00:26:08+00:00","author":{"@id":"https:\/\/bridgebio.com\/#\/schema\/person\/4add0b7d61d0ea7518a9f18377b57f96"},"breadcrumb":{"@id":"https:\/\/bridgebio.com\/news\/bridgebio-to-present-additional-analyses-from-the-phase-3-attribute-cm-trial-of-acoramidis-in-patients-with-transthyretin-amyloid-cardiomyopathy-attr-cm-at-the-esc-congress-2024-and-the-hfsa-annual\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/bridgebio.com\/news\/bridgebio-to-present-additional-analyses-from-the-phase-3-attribute-cm-trial-of-acoramidis-in-patients-with-transthyretin-amyloid-cardiomyopathy-attr-cm-at-the-esc-congress-2024-and-the-hfsa-annual\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/bridgebio.com\/news\/bridgebio-to-present-additional-analyses-from-the-phase-3-attribute-cm-trial-of-acoramidis-in-patients-with-transthyretin-amyloid-cardiomyopathy-attr-cm-at-the-esc-congress-2024-and-the-hfsa-annual\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/bridgebio.com\/"},{"@type":"ListItem","position":2,"name":"BridgeBio to Present Additional Analyses from the Phase 3 ATTRibute-CM Trial of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the ESC Congress 2024 and the HFSA Annual Meeting 2024"}]},{"@type":"WebSite","@id":"https:\/\/bridgebio.com\/#website","url":"https:\/\/bridgebio.com\/","name":"BridgeBio","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/bridgebio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/bridgebio.com\/#\/schema\/person\/4add0b7d61d0ea7518a9f18377b57f96","name":"Holly Condon","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/bridgebio.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/32160078eac50cc259c3cf6057162339?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/32160078eac50cc259c3cf6057162339?s=96&d=mm&r=g","caption":"Holly Condon"},"url":"https:\/\/bridgebio.com\/author\/holly-condonbridgebio-com\/"}]}},"_links":{"self":[{"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/posts\/6751"}],"collection":[{"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/users\/38"}],"replies":[{"embeddable":true,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/comments?post=6751"}],"version-history":[{"count":0,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/posts\/6751\/revisions"}],"wp:attachment":[{"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/media?parent=6751"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/categories?post=6751"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/tags?post=6751"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}